{
  "id": 3807379,
  "title": "Adicet Bio receives FDA clearance for prostate cancer trial",
  "url": "https://urgent.news/2026/08/27/adicet-bio-receives-fda-clearance-for-prostate-cancer-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T20:04:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/adicet-bio-receives-fda-clearance-for-prostate-cancer-trial-93CH-4880083"
  },
  "original_language": "en",
  "account": "Redwood City, Calif. - Adicet Bio Inc. announced on Wednesday that the FDA has approved its Investigational New Drug application for ADI-212, a treatment for advanced prostate cancer. ADICET Bio plans to initiate Phase 1 enrollment of patients with metastatic castration-resistant prostate cancer in the fourth quarter of 2026. ADI-212 is a gene-edited cell therapy candidate targeting the prostate-specific membrane antigen. This treatment consists of a CAR binder designed to recognize tumors, combined with membrane-tethered IL-12 and CRISPR/Cas9-mediated modification of subunit 12 of the mediator complex. Blake Aftab, Adicet Bio's Chief Scientific Officer, noted that ADI-212 is a significant milestone in the company's approach to tackling solid tumors and adds to their portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs. The FDA clearance enables Adicet Bio to advance to clinical trials in humans, where Phase 1 trials will focus on the safety and dosage of the new treatment.",
  "summary": null,
  "key_points": [
    "FDA clears Adicet Bio's ADI-212 for prostate cancer trial",
    "Phase 1 enrollment planned for metastatic castration-resistant prostate cancer patients in Q4 2026",
    "CAR binder and membrane-tethered IL-12 target prostate-specific membrane antigen"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}